Safety and tolerability of multiple ascending doses of once-weekly GL0034 (utreglutide) in healthy individuals

被引：0
|
作者：
Burade, V. [1 ]
Thennati, R. [1 ]
Natarajan, M. [1 ]
Shahi, P. [1 ]
Nagaraja, R. [1 ]
Panchal, S. [1 ]
Agrawal, S. [1 ]
Jandrain, B. [2 ,3 ]
Duvauchelle, T. [4 ]
Garcia-Ocana, A. [5 ]
Rutter, G. A. [6 ,7 ]
Pratley, R. E. [8 ]
Thorens, B. [9 ]
Vilsboll, T. [10 ,11 ]
机构：
[1] Sun Pharmaceut Ind Ltd, High Impact Innovat Sustainable Hlth Solut HISH, Vadodara, Gujarat, India
[2] Acad Hosp Leige, Clin Pharmacol Unit, ATC Co, Liege, Belgium
[3] Acad Hosp Leige, Div Diabet Nutr & Metab Disorders, Liege, Belgium
[4] Phaster1, La Plessis Trevise, France
[5] Arthur Riggs Diabet & Metab Res Inst, Dept Mol & Cellular Endocrinol, Ruth B & Robert K Lanman Endowed Chair Gene Regul, Duarte, CA USA
[6] Univ Montreal, CR CHUM, Montreal, PQ, Canada
[7] Imperial Coll London, Div Diabet Endocrinol & Metab, Sect Cell Biol & Funct Genom, Dept Metab Digest Reprod, London, England
[8] AdventHlth Translat Res Inst, Orlando, FL USA
[9] Univ Lausanne, Ctr Integrat Genom, Lausanne, Switzerland
[10] Steno Diabet Ctr Copenhagen, Clin Res, Herlev, Denmark
[11] Univ Copenhagen, Copenhagen, Denmark
来源：
DIABETOLOGIA | 2023年 / 66卷 / SUPPL 1期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
641
引用
收藏
页码：S323 / S323
页数：1
相关论文
共 50 条
  • [1] Safety and Tolerability of Once-Weekly GL0034 (Utreglutide) in Healthy Individuals-A Multiple Ascending Dose Study
    Thennati, Rajamannar
    Burade, Vinod S.
    Natarajan, Muthukumaran
    Shahi, Pradeep
    Nagaraja, Ravishankara
    Panchal, Satish T.
    Agrawal, Sudeep K.
    Jandrain, Bernard
    Duvauchelle, Thierry
    Garcia-Ocana, Adolfo
    Rutter, Guy A.
    Pratley, Richard E.
    Thorens, Bernard
    Vilsboll, Tina
    DIABETES, 2023, 72
  • [2] Safety, Tolerability, and Metabolic Effects of Once-Weekly GL0034 (Utreglutide) in Individuals with Obesity-A Multiple Ascending Dose Study
    Thennati, Rajamannar
    Burade, Vinod S.
    Natarajan, Muthukumaran
    Shahi, Pradeep
    Nagaraja, Ravishankara
    Agrawal, Sudeep K.
    Duvauchelle, Thierry
    Garcia-Ocana, Adolfo
    Rutter, Guy A.
    Pratley, Richard E.
    Thorens, Bernard
    Vilsboll, Tina
    DIABETES, 2024, 73
  • [3] Safety, tolerability and metabolic effects of once weekly GL0034 (Utreglutide) in individuals with obesity: a multiple ascending dose study
    Thennati, R.
    Burade, V.
    Nagarajan, M.
    Shahi, P.
    Nagaraja, R.
    Agrawal, S.
    Duvauchelle, T.
    Garcia-Ocana, A.
    Rutter, G.
    Pratley, R. E.
    Thorens, B.
    Vilsboll, T.
    DIABETOLOGIA, 2024, 67 : S359 - S360
  • [4] A Single Ascending Dose Study of the Novel GLP-1 Receptor Agonist GL0034 (Utreglutide) in Obese Individuals without Diabetes
    Thennati, Rajamannar
    Burade, Vinod S.
    Natarajan, Muthukumaran
    Shahi, Pradeep
    Nagaraja, Ravishankara
    Panchal, Satish T.
    Agrawal, Sudeep K.
    Jandrain, Bernard
    Duvauchelle, Thierry
    Garcia-Ocana, Adolfo
    Rutter, Guy A.
    Pratley, Richard E.
    Thorens, Bernard
    Vilsboll, Tina
    DIABETES, 2023, 72
  • [5] A single ascending dose study of the novel GLP-1 receptor agonist GL0034 (utreglutide) in individuals with obesity without diabetes
    Thennati, R.
    Burade, V.
    Natarajan, M.
    Shahi, P.
    Nagaraja, R.
    Panchal, S.
    Agrawal, S.
    Jandrain, B.
    Duvauchelle, T.
    Garcia-Ocana, A.
    Rutter, G. A.
    Pratley, R. E.
    Thorens, B.
    Vilsboll, T.
    DIABETOLOGIA, 2023, 66 (SUPPL 1) : S320 - S321
  • [6] Safety and tolerability for once-weekly Rifapentine plus Isoniazid in Taiwan
    Chan, Pei-Chun
    Lee, Pin-Hui
    Lu, Min-Ju
    Huang, You-Chieh
    Huang, Shu-Hua
    Huang, Yen-Fang
    INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2017, 50 : S159 - S160
  • [7] Tolerability, Safety, and Pharmacokinetics of Once-Weekly Administration of GLP-1 Analogue in Healthy Subjects
    Xu, Michael M.
    DIABETES, 2015, 64 : A72 - A73
  • [8] GL0034 (Utreglutide), a novel, long acting, glucagon-like peptide 1 receptor agonist (GLP-1 RA), results of a phase 1 study in healthy individuals
    Thennati, Rajamannar
    Burade, Vinod
    Natarajan, Muthukumaran
    Shahi, Pradeep
    Nagaraja, Ravishankara
    Panchal, Satish
    Agrawal, Sudeep
    Jandrain, Bernard
    Duvauchelle, Thierry
    Pratley, Richard E.
    Thorens, Bernard
    Vilsboll, Tina
    JOURNAL OF HEPATOLOGY, 2023, 78 : S607 - S608
  • [9] Once Weekly Utreglutide (GL0034), a Glucagon-like Peptide-1 Receptor Agonist, at 4 x 450 μg Doses Reduces Blood Pressure, Lipids, and Body Weight in Post-menopausal Females: A Phase I Study
    Thennati, Rajamannar
    Burade, Vinod
    Natarajan, Muthukumaran
    Shahi, Pradeep
    Nagaraja, Ravishankara
    Agrawal, Sudeep
    Duvauchelle, Thierry
    Pratley, Richard
    Thorens, Bernard
    Vilsboll, Tina
    CIRCULATION, 2024, 150
  • [10] Pharmacokinetics, pharmacodynamics, safety and tolerability of multiple ascending doses of ticagrelor in healthy volunteers
    Butler, Kathleen
    Teng, Renli
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2010, 70 (01) : 65 - 77
12345